9:22 AM
Leo Group India
| ||
| Teva Pharmaceutical Industries subpoenaed by SEC over antibribery compliance Economic Times Israel's Teva Pharmaceutical Industries, the world's biggest generic-drug maker, is being investigated by the US securities regulator over the company's compliance with a US law that prohibits bribery of foreign officials. In a filing with the US Securities and ... See all stories on this topic » | ||
| KV Pharmaceutical Files for Chapter 11 Wall Street Journal K-V Pharmaceutical Co. filed for Chapter 11 bankruptcy, a move it said was propelled by the U.S. Food and Drug Administration's failure to enforce orphan drug exclusivity granted to K-V's key premature-birth drug, Makena. Chief Executive Greg Divis called ... See all stories on this topic » | ||
| KV Pharmaceutical Files for Chapter 11; Cites Makena Drug Woes Wall Street Journal By Saabira Chaudhuri. K-V Pharmaceutical Co. (KVA, KVB) filed for Chapter 11 bankruptcy, a move it said was propelled by the U.S. Food and Drug Administration's failure to enforce orphan drug exclusivity granted to K-V's key premature-birth drug, Makena. See all stories on this topic » | ||
| KV Pharmaceutical Announces Planned Transition of Trading of Class A and ... MarketWatch (press release) About K-V Pharmaceutical Company. K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. As such, we are committed to advancing the health of women across all the stages of ... See all stories on this topic » | ||
| US drug maker Mylan enters Indian market Livemint "We see significant growth potential in India, the world's second largest pharmaceutical market by volume, and look forward to continuing to expand our operations in India in additional therapeutic categories," Mylan's chief executive officer Heather Bresch ... See all stories on this topic » | ||
| Pharmaceutical Industry Veteran Al Altomari Elected To Insmed's Board Of ... MarketWatch (press release) "Al brings to our Board nearly 30 years of valuable experience in the pharmaceutical industry, including more than 20 years focused on the development and marketing of specialty pharmaceutical products," said Donald J. Hayden, Insmed's Executive ... See all stories on this topic » | ||
| Amneal Pharmaceuticals Bucks Trend and Adds US Manufacturing Jobs with ... MarketWatch (press release) BRIDGEWATER, N.J., Aug 06, 2012 (BUSINESS WIRE) -- Amneal Pharmaceuticals, LLC today announced that the company is investing $120 million in physical plant capital expenditures from 2012-2014 to significantly grow its operations at three of its six ... See all stories on this topic » | ||
| K-V Pharmaceutical Announces Planned Transition of Trading of Class A and ... Sacramento Bee 6, 2012 -- /PRNewswire/ -- K-V Pharmaceutical Company (NYSE: KVa / KVb) ("K-V" or "the Company") today announced that its Class A and Class B common shares may be traded in the over the counter (OTC) market following the Company's suspension ... See all stories on this topic » | ||
| Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study of RX ... MarketWatch (press release) ROCKVILLE, Md., Aug 06, 2012 (BUSINESS WIRE) -- Rexahn Pharmaceuticals, Inc. (ASE:RNN) , a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment